nivolumab
FDA Approves Opdivo With Yervoy for Unresectable or Metastatic Hepatocellular Carcinoma
The FDA has approved Opdivo with Yervoy for the first-line treatment of adult patients with unresectable or ...
APRIL 14, 2025
Nivolumab Scores in Bladder and Renal Cancer Trials
Providing adjuvant nivolumab after radical resection continues to yield clinically meaningful disease-free survival ...
APRIL 10, 2025
FDA Approves Opdivo With Yervoy for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
The FDA has approved Opdivo with Yervoy for unresectable or metastatic microsatellite instability−high or ...
APRIL 9, 2025
FDA Approves Neoadjuvant/Adjuvant Opdivo for Resectable NSCLC
The FDA approved Opdivo with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent ...
OCTOBER 4, 2024
FDA Approves Opdivo for Adjuvant Treatment of Select Patients With Stage IIB/C Melanoma
The FDA approved nivolumab (Opdivo, Bristol Myers Squibb) for the adjuvant treatment of completely resected stage ...
OCTOBER 17, 2023
Improving Outcomes in Patients With Bladder Cancer
The immunotherapy Opdivo given after surgery increased bladder cancer patients’ chance of staying cancer-free ...
APRIL 13, 2023
Nivolumab Indicated as Neoadjuvant NSCLC Treatment
The FDA approved nivolumab (Opdivo, Bristol Myers Squibb) in combination with platinum-doublet chemotherapy to ...
APRIL 12, 2022
Nivolumab Plus Relatlimab Approved to Treat Metastatic Melanoma
The FDA approved a fixed-dose combination of the programmed death-1–blocking antibody nivolumab and ...
MARCH 22, 2022
FDA Grants New Indication for Opdivo for Resected Esophageal or GEJ Cancer
The FDA granted a new indication for nivolumab (Opdivo, Bristol Myers Squibb) for the treatment of patients with ...
JUNE 7, 2021
Opdivo Approved for First-Line Treatment of Advanced or Metastatic GI Cancers
The FDA approved nivolumab (Opdivo, Bristol Myers Squibb), in combination with fluoropyrimidine- and ...
APRIL 27, 2021
Weight-Based Nivolumab Dosing Yields Substantial Savings
HOPA 2019: Implementation of a weight-based, dose-capping protocol for nivolumab resulted in substantial cost ...
APRIL 5, 2019
FDA Approves Opdivo as Third-Line Rx for SCLC
The FDA granted accelerated approval to nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of patients with ...
AUGUST 21, 2018
